Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Men or women at least 18 years of age at time of consent
Chronic plaque-type psoriasis diagnosed for at least 6 months at time of randomization
At time of randomization, moderate to severe psoriasis as defined by:
At screening and randomization, chronic plaque-type psoriasis considered inadequately controlled by:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
404 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal